BioSpace News Archive

PureTech Health plc, a clinical-stage biotherapeutics company noted that its Founded Entity, Vedanta Biosciences, Inc., announced the details of three podium presentations of research informed by multiple clinical studies at Digestive Disease Week 2022, being held both virtually and in person in San Diego, CA on May 21-24.

Northwest Specialty Hospital now hosts the most advanced collection of spinal surgical technology in the country.

MannKind Corporation celebrated that the U.S. Food and Drug Administration has approved United Therapeutics’ Tyvaso DPI™ inhalation powder for the treatment of patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

United Therapeutics Corporation, a public benefit corporation, announced that the U.S. Food and Drug Administration has approved Tyvaso DPI™ inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease to improve exercise ability.

SpringWorks Therapeutics, Inc. announced positive topline results from the DeFi trial, a double-blind, placebo-controlled Phase 3 trial evaluating the efficacy, safety and tolerability of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors.

Pfizer Inc. announced detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluating etrasimod, a once-daily, oral, selective sphingosine 1-phosphate receptor modulator for the treatment of moderately-to-severely active ulcerative colitis.

nSyneos Health®, the only fully integrated biopharmaceutical solutions organization, announced that the Company is scheduled to present at two upcoming investor conferences.

Everest Medicines (HKEX 1952.HK) announced today that its licensing partner, Pfizer Inc. (NYSE: PFE) presented at Digestive Disease Week (DDW) 2022 detailed results from two pivotal studies that make up the ELEVATE UC Phase 3 registrational program evaluating etrasimod.

Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today that its study in 926 DCIS patients demonstrating the clinical utility of DCISionRT® was selected for an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting.

MeaTech 3D Ltd. (Nasdaq: MITC), an international deep-tech company at the forefront of the cultured meat revolution, is pleased to announce today that CEO Arik Kaufman will be presenting at the 12th annual LD Micro Invitational Conference on Wednesday, June 8th at 4:00 p.m. PT at the Four Seasons in Westlake Village, California.